Axsome Therapeutics to Launch Auvelity for Alzheimer's Agitation This Month

Key Facts

As biotechnology firms race to strengthen their central nervous system portfolios, Axsome Therapeutics is preparing to launch its drug Auvelity for Alzheimer's disease agitation this month. According to reports, the company is moving to commercialize this treatment while simultaneously expanding its application to include major depressive disorder. This strategic move aims to broaden the market reach of its existing pipeline into new therapeutic indications.

This launch occurs amid intense competition in the neuro-specialty market, where peers such as Biogen and Sage Therapeutics have also been active. Per market data, Axsome's valuation reflects investor optimism regarding its CNS pipeline, especially as analysts project the Alzheimer's agitation market could reach multi-billion dollar levels by 2030 (per GlobalData research). The commercial success of Auvelity is viewed as a primary catalyst for the company's revenue growth in the coming quarters.

Traders are closely monitoring AXSM stock levels as the commercial rollout begins. Market sentiment in the growth and biotech sectors may also be influenced by broader economic indicators, such as the US ISM Manufacturing PMI which printed at 54 on June 1, 2026, exceeding forecasts. Investors should watch for initial prescription data and adoption rates following this month's official launch.